Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

MET Mutation Associated with Responsiveness to Crizotinib

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Joline S. W. Lind, MBBS, Egbert F

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Bilateral Patellar Metastases from Non-small Cell Lung Cancer

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

Vertebral Collapse Caused by Bone Metastasis

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels Lee M. Krug, MD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Tumor Response Kinetics after Schedule-Dependent Paclitaxel Chemoradiation Treatment for Inoperable Non-small Cell Lung Cancer: A Model for Low-Dose.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Bronchoepidural Fistula in a Man with Actinomycosis Complicated Non-small Cell Lung Cancer Mun Sem Liew, MBBS, BMedSci, Surein Arulananda, MBBS, BMedSci,

Ethnic Differences in the Management of Lung Cancer in New Zealand

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

European Lung Cancer Conference (ELCC) 2016 Organisation

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

S-1 Treatment for Chemorefractory Thymic Carcinoma

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

David Garfield, MD Journal of Thoracic Oncology

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report Joline S.W. Lind, MBBS, MA, Pieter E. Postmus, MD, PhD, Egbert F. Smit, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 4, Pages 554-557 (April 2010) DOI: 10.1097/JTO.0b013e3181d3e47e Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Axial, contrast-enhanced computed tomography (CT) image of the thorax before erlotinib showed (A) an osteolytic bone metastases in the right acromium (arrow). (B) Three months after starting erlotinib, increased osteosclerosis was seen at the site of this metastasis (arrow). Journal of Thoracic Oncology 2010 5, 554-557DOI: (10.1097/JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Axial, contrast-enhanced computed tomography (CT) image of the thorax at the time of diagnosis showed (A) an osteolytic bone metastasis in the 12th thoracic vertebra (arrow). A CT scan after 6 weeks of erlotinib treatment showed (B) osteoblastic activity in the metastasis of the 12th thoracic vertebra (arrow) and (D) an osteoblastic lesion in the third thoracic vertebra (arrow) not visible at baseline (C). Journal of Thoracic Oncology 2010 5, 554-557DOI: (10.1097/JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Axial, contrast-enhanced computed tomography (CT) image of the thorax before low-dose erlotinib showed (A) osteolytic bone metastases in the sternum and thoracic vertebra (arrows) and (B) mild osteoblastic activity in the lumbar vertebra (arrow). A CT scan after 10 weeks of erlotinib treatment showed (B) marked osteoblastic activity in the sternum (arrow), osteosclerosis around the metastases in the thoracic vertebrae (arrow), and (D) diffuse, increased osteosclerosis in the lumbar vertebra. Journal of Thoracic Oncology 2010 5, 554-557DOI: (10.1097/JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions